Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 9/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136968 | 0.84 | SMN1; SMN2 (0.48) | HPGDL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL6137351 | 0.77 | RORC (0.50) | HPGDF2RL3SCN9A | |
| SCHEMBL6354434 | 0.74 | DGAT2 (0.40) | HPGDL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL6136810 | 0.73 | ALDH1A1 (0.54) | HPGDMEN1KMT2AF2RL3SCN9A | |
| SCHEMBL6139715 | 0.73 | MEN1 (0.43) | HPGDL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL6137028 | 0.73 | RORC (0.59) | HPGDSCN9A | |
| SCHEMBL6136923 | 0.72 | MAPK8 (0.55) | HPGDL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL6136872 | 0.72 | RORC (0.47) | HPGDL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL6136884 | 0.67 | RORC (0.66) | HPGD | |
| SCHEMBL6363756 | 0.66 | DGAT2 (0.41) | HPGDL3MBTL1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED | 2005-10-13 | — | — | US | disclosed |
| EP-1140856-B1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2005-04-27 | — | — | EP | disclosed |
| EP-1140856-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | Novartis AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED (AT) | 2001-06-28 | — | — | US | disclosed |
| US-6207831-B1 | A BENZOPYRAZOLE COMPOUND | NOVARTIS AG (CH) | 2001-03-27 | — | — | US | disclosed |
| WO-2000037448-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLC43A1, CUTA, ANXA1 | HPGD 4341/4885L3MBTL1 1660/4885MEN1 2066/4885 |
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLCO1A2, ABCG2, SLCO1B1 | HPGD 2745/4885L3MBTL1 3846/4885MEN1 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.